With guest host John Donvan.
When a patient has run out of options, should new options be put on the table?
The U.S. Senate said Yes to that question this month by approving so-called right-to-try legislation, which lets patients request drugs and treatments that are still in clinical trials and haven’t yet been approved for the market.
More than half of U.S. states have passed similar legislation, despite some concerns that patients could be exploited by the companies behind the previously unavailable treatments.
Is this a risk for patients seeking any sign of hope, or another step toward letting Americans control how they handle their lives … and deaths?
GUESTS
Starlee Coleman, Vice President of Communications for the Goldwater Institute
Sarah Karlin-Smith, Healthcare reporter, Politico
Ameet Sarpatwari, Assistant Director of the Program on Regulation Therapeutics and the Law at Brigham and Women’s Hospital and Harvard Medical School
David Farber, Partner in the FDA and Life Sciences Practice at the law firm of King and Spalding
For more, visit http://the1a.org.
© 2017 WAMU 88.5 – American University Radio.
Copyright 2020 WAMU 88.5. To see more, visit WAMU 88.5. 9(MDAyNDY5ODMwMDEyMjg3NjMzMTE1ZjE2MA001))